TORZIFYX
Dead / Abandoned — Abandoned — no statement of use filed (as of 10 Feb 2020)
What this means for you
This application is over — abandoned 10 Feb 2020. The name may be available, but check before relying on it — rights can also come from actual use, not only from the register.
Record
- Serial number
- 88229101
- Mark type
- Stylized text
- Filed
- 13 Dec 2018
- Published for opposition
- 14 May 2019
- Abandoned
- 10 Feb 2020
- Attorney of record
- Chelsea E. Carbone
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for the treatment and prevention of cancer, cardiovascular disease, epilepsy and mitochondrial disease; vaccine preparations; pharmaceutical preparations, namely, a drug formulation comprising nanoparticles of sirolimus and albumin for use in angiology, cardiology, endocrinology, gastroenterology, geriatrics, hematology, hepatology, nephrology, neurology, oncology, pulmonology, pneumology, respirology, rheumatology, anesthesiology, urology, dermatology, gynecology, ophthalmology, infectiology, and psychiatry; pharmaceutical preparations, namely, a drug formulation comprising nanoparticles of sirolimus and albumin for use in in pediatric, geriatric, emergency, family, and human preventative medicine; Pharmaceutical preparations for the treatment of cancer, cardiovascular disease, epilepsy and mitochondrial disease
- Class 042 — Scientific and technological services: Medical and pharmaceutical research services; pharmaceutical research and development; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; medical and scientific research, namely, conducting clinical trials for others; laboratory research services relating to pharmaceuticals; scientific and technological services, namely, scientific research services in the field of process development, validation, qualification, and manufacturing of pharmaceuticals and biopharmaceuticals; scientific research and technological services consultation services in the field of development, manufacturing and testing of pharmaceuticals and biopharmaceuticals; providing product research and development in the pharmaceutical field for purposes of process development, validation, qualification, and manufacturing of pharmaceuticals and biopharmaceuticals; scientific research and technological consultation services in the field of pharmaceutical research and pharmacology; custom development of pharmaceutical, biopharmaceutical and chemical products; providing evaluation testing for pharmaceutical, biopharmaceutical and chemical products, and medical devices featuring testing for safety, toxicity, content, identity, purity, configuration and function for others, using chemical, in vitro or in vivo assays, analyses and models; pre-clinical and non-clinical evaluation testing of pharmaceutical, biopharmaceutical and chemical products performed primarily using animals and other biological models; pharmaceutical, biopharmaceutical, and chemical research and development for others; pharmaceutical research in the fields of angiology, cardiology, endocrinology, gastroenterology, geriatrics, hematology, hepatology, nephrology, neurology, oncology, pulmonology, pneumology, respirology, rheumatology, anesthesiology, urology, dermatology, gynecology, ophthalmology, infectiology, and psychiatry; pharmaceutical research for use in pediatric, geriatric, emergency, family, and preventative medicine; pharmaceutical research for the treatment of infectious, deficiency, hereditary, and physiological diseases
Owner
- AADi Bioscience, Inc., Pacific Palisades, CA, US
- AADi Bioscience, Inc., Pacific Palisades, CA, US
Prosecution history
- 10 Feb 2020 — ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
- 10 Feb 2020 — ABANDONMENT - NO USE STATEMENT FILED
- 09 Jul 2019 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 14 May 2019 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 14 May 2019 — PUBLISHED FOR OPPOSITION
- 24 Apr 2019 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 08 Apr 2019 — ASSIGNED TO LIE
- 15 Mar 2019 — EXAMINER'S AMENDMENT ENTERED
- 15 Mar 2019 — NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
- 15 Mar 2019 — EXAMINERS AMENDMENT E-MAILED
- 15 Mar 2019 — EXAMINERS AMENDMENT -WRITTEN
- 11 Mar 2019 — ASSIGNED TO EXAMINER
- 06 Jan 2019 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
- 17 Dec 2018 — NEW APPLICATION ENTERED
- 18 Mar 2019 — APPROVED FOR PUB - PRINCIPAL REGISTER